T cell therapies involving CD8+ T cells, cytotoxic T lymphocytes, and CD4+ helper cells can be utilized to recognize and directly neutralize cancer cells.(1,2) Therefore, T-cell therapy with anti-programmed death receptor 1 (IPD-1) is a plausible alternative for treating resistant cancer.(2,3). This evidence concerns the gene CD8A and cancer.